MedPath

Alternative Treatments for Menopausal Women

Not Applicable
Completed
Conditions
Osteoporosis
Hot Flushes
Dyslipidemia
Menopause
Interventions
Dietary Supplement: Red Clover extract
Dietary Supplement: Placebo
Registration Number
NCT02028702
Lead Sponsor
Aarhus University Hospital
Brief Summary

To investigate the reported health benefits (lipid profile, inflammatory factors, cardiovascular status and bone density) of a novel, phytoestrogen rich, Red Clover treatment on women suffering from both menopause related primary (hot flushes, night sweats, sleep disturbance and weight gain) and secondary (osteoporosis, cardiovascular and changes in lipid metabolism) symptoms.

Detailed Description

Menopausal symptoms are a common phenomenon causing discomfort to many middle aged women throughout the world. The core symptoms are experienced as hot flushes (HF), night sweats, vaginal dryness and sleep disturbance. Other secondary symptoms are sexual dysfunction, depression, anxiety, memory loss, fatigue, headache, joint pains and weight gain. Moreover there is increased risk of further complications such as osteoporosis, cardiovascular and negative changes in lipid profile associated with the reduction in oestrogen during and post menopause.

Trifolium Pratense or Red Clover (RC) has arisen as a popular source for women experiencing HF because it contains a variety of phytoestrogen's, namely isoflavones, lignans and coumestans. Phytoestrogens are shown to have positive effects on menopausal disorders such as breast cancer, cardiovascular risk factors, osteoporosis and have been shown to exert non-hormonal antioxidant effects. Additionally these isoflavones appear to reduce bone resorbtion, help maintain bone mineral density and improve lipid profile (reducing LDL: HDL, lipoprotein A, total cholesterol and may also reduce triglycerides).

RC is particularly high in estrogenic isoflavones biochanin A, formononetin and to a lesser degree genestein and diadzein, although the two former are precursors to genestein and diadzein. Asian populations with a high intake of soy (rich in genestein and diadzein) have long shown a lower reported incidence of the symptoms of menopause.

The study will be carried out as a 3-month parallel randomized control intervention study, consisting of 61 menopausal women. During summer 2012, 61 participants will be randomised into 2 groups (\~30-31 in each group). The two groups are as follows:

1. Menopausal women receiving RC treatment - 150ml/d Red Clover (80mg/d of isoflavones as aglycone)

2. Menopausal women receiving placebo - 150ml placebo

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
61
Inclusion Criteria
  • Women aged 40-65 years
  • Experiencing daily hot flushes
  • Body Mass Index (BMI) between 20-40
  • Irregular menstrual bleeding
  • FSH levels above the normal range
Exclusion Criteria
  • Simultaneous participation in other clinical trials within the last 3 months
  • Severe cardiovascular, psychiatric, neurological, and/or kidney disease.
  • Alcohol or drug abuse and acute illness.
  • Blood pressure > 160/110
  • Pregnant and lactating women

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Red Clover extractRed Clover extract150 ml/d Red Clover extract
PlaceboPlacebo150 ml/d sweetened and coloured water
Primary Outcome Measures
NameTimeMethod
Primary Menopause-related symptoms3 months

To examine the extent to which red clover extract can reduce the frequency and intensity of hot flashes, sleep disturbances and flush related sweats.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Center for Clinical Research, Hospital Vendsyssel

🇩🇰

Hjorring, Nordjylland, Denmark

© Copyright 2025. All Rights Reserved by MedPath